Consensus Vericel Corporation

Stocks

VCEL

US92346J1088

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-18 EDT			5-day change	1st Jan Change
40.02 ^USD	-0.02%		+4.38%	+11.14%

09-15	Vericel Corporation Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 02:35 PM
07-31	Truist Raises Price Target on Vericel to $58 From $54, Keeps Buy Rating	MT

Evolution of the Average Target: Vericel Corporation

Evolution of the Target Price: Vericel Corporation

Changes in Analyst Recommendations: Vericel Corporation

98faaede998.CujkimKXpVbNdKXqS1XVdcapMjvP9Du1aC0s4-nZzJc.XdDd3BT8zCKJFcSAfAqbQvbtQm7-jkzXBBR2jN2v-fJTor3IFM7oJ4Akwg~0d2d8a81d9bcc61831e29928bfeee10f

Analysts' recommendations: Vericel Corporation

07-31	Truist Raises Price Target on Vericel to $58 From $54, Keeps Buy Rating	MT
07-16	Truist Securities Adjusts Price Target on Vericel to $54 From $42, Maintains Buy Rating	MT
04-15	Truist Cuts Price Target on Vericel to $42 From $48, Keeps Buy Rating	MT
02-27	Truist Raises Price Target on Vericel to $48 From $45, Keeps Buy Rating	MT
12-18	Truist Securities Adjusts Price Target on Vericel to $45 From $50, Maintains Buy Rating	MT
11-10	Truist Raises Price Target on Vericel to $50 From $41, Keeps Buy Rating	MT
25-09-17	Vericel Shares Lower After BTIG Downgrade	MT
25-09-17	BTIG Downgrades Vericel to Neutral From Buy	MT
25-07-31	Biologics company Vericel's Q2 revenue misses expectations	RE
25-05-09	Truist Securities Adjusts Price Target on Vericel to $52 From $51, Maintains Buy Rating	MT
25-04-11	Truist Cuts Price Target on Vericel to $51 From $61, Keeps Buy Rating	MT
25-02-28	Truist Securities Cuts Price Target on Vericel to $61 From $67, Keeps Buy Rating	MT
24-12-18	Truist Securities Raises Price Target on Vericel to $67 From $61, Keeps Buy Rating	MT
24-11-11	Truist Securities Raises Price Target on Vericel to $61 From $57, Maintains Buy Rating	MT
24-08-09	Canaccord Genuity Initiates Vericel at Buy With $57 Price Target	MT
24-07-16	Truist Lifts Price Target on Vericel to $57 From $56, Maintains Buy Rating	MT
24-06-20	TD Cowen Initiates Vericel at Buy With $55 Price Target	MT
24-03-01	Truist Securities Raises Vericel's Price Target to $54 From $51, Keeps Buy Rating	MT
24-03-01	HC Wainwright Adjusts Price Target on Vericel to $53 From $46, Keeps Buy Rating	MT
23-09-21	HC Wainwright Adjusts Price Target on Vericel to $44.50 From $41, Keeps Buy Rating	MT
23-08-08	BTIG Research Upgrades Vericel to Buy From Neutral, $39 Price Target	MT
23-08-03	HC Wainwright Adjusts Price Target on Vericel to $41 From $37, Maintains Buy Rating	MT
23-07-19	Truist Securities Adjusts Price Target on Vericel to $42 From $36, Maintains Hold Rating	MT
23-05-11	Truist Securities Adjusts Price Target on Vericel to $36 From $31, Maintains Hold Rating	MT
23-05-11	Stephens Adjusts Vericel Price Target to $42 From $39, Maintains Overweight Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERICEL CORPORATION					+51.32%
	REGENERON PHARMACEUTICALS, INC.					+7.58%
	CSL LIMITED					+0.05%
	MODERNA, INC.					-24.37%
	SAMSUNG BIOLOGICS CO.,LTD.					+40.94%
	UCB					+36.63%
	BIOGEN INC.					+8.73%
	INCYTE CORPORATION					+0.09%
	INNOVENT BIOLOGICS, INC.					+34.19%
	SWEDISH ORPHAN BIOVITRUM AB					+12.36%
	Average					+16.75%
	Weighted average by Cap.					+10.11%